The EURORealTime SARS-CoV-2 is a multi-plex PCR-based test for fast and efficient detection of SARS-CoV-2, including the new variant omicron (B.1.1.529 lineage), as well as alpha (B.1.1.7 lineage), beta (B.1.351 lineage), gamma (P.1 lineage), delta (B1.617.2 lineage), lambda (C.37 lineage) and mu (B.1.621 lineage).
Reverse transcription and real-time PCR are performed in one step, so that only one reaction is required per sample. The detection of SARS-CoV-2 is based on two defined target sequences in the ORF1ab and N genes of the viral genome, ensuring high sensitivity.
A further test, the EURORealTime SARS-CoV-2/Influenza A/B, provides combined testing for SARS-CoV-2 and influenza virus types A and B. This assay aids discrimination between the clinically overlapping diseases COVID-19 and influenza, identification of potential co-infections and epidemiological surveillance.
The efficient parallel testing saves time and resources, enabling more patient analyses to be performed per day and helping to conserve laboratory materials that are in short supply. Both EURORealTime assays incorporate numerous controls, including an internal amplification control and a positive control, to ensure reliable results.
The assays are CE-marked and validated for commonly used real-time PCR cyclers. Complementary EURORealTime Analysis software provides fully automated and standardised evaluation and documentation of results, including all control results. Comprehensive automation options for sample preparation, PCR setup and PCR performance are available.